 | | Vol. 12.46 – 23 November, 2021 |
| |
|
|
| Researchers found that 41 and 84 microRNA inhibitors enhanced the sensitivity of Capan1 and MiaPaCa2 pancreatic ductal adenocarcinoma cells respectively.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists assessed the roles of GRP75, other than as a component, in insulin action in both in vitro and in vivo models with insulin resistance.
[Diabetes] |
|
|
|
| The authors isolated pancreatic islets from adult male wistar rats and identified pancreatic β-cells by the cell size, capacitance and membrane potential.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Scientists analyzed stage-specific RNA-, ChIP-, and ATAC-sequencing data to dissect transcriptional and regulatory mechanisms during pancreatic development.
[Communications Biology] |
| |
|
|
| The authors identified the prognostic significance and therapeutic options of metabolic subtypes of resectable pancreatic cancer.
[Cellular Oncology] |
|
|
|
| Investigators ectopically expressed α1,4-N-acetylglucosaminyltransferase (α4GnT), the α1,4-linked N-acetylglucosamine biosynthetic enzyme, together with MUC6 in the human pancreatic cancer cell lines MIA PaCa-2 and PANC-1, neither of which expressed α4GnT and MUC6.
[Cancer Science] |
|
|
|
| Lutein is a natural compound that belongs to the non-vitamin A carotenoids family and has presented antitumor effects on multiple cancer types. The authors explored the role of lutein in pancreatic adenocarcinoma progression.
[Journal of Biochemical and Molecular Toxicology] |
|
|
|
| Scientists examined the expression of miR‑190b in pancreatic cancer cell lines and tissues and evaluated its effects on cancer progression.
[Oncology Reports] |
|
|
|
| Researchers knocked down XRCC1 expression by using pLVX-shXRCC1 in the MiaPaCa2 cells and BxPC3 cells and evaluated β-lapachone-induced DNA lesions by γH2AX foci formation and alkaline comet assay.
[BMC Cancer] |
|
|
|
| Secretome analysis was performed in pancreatic cancer stem cell-enriched spheres and control adherent cells for biomarker discovery.
[BMC Cancer] |
|  |
|
|
|
| Scientists review current knowledge of pancreatic ductal adenocarcinoma evolution and heterogeneity, gained from the study of preclinical models and patient biospecimens.
[Nature Reviews Cancer] |
|
|
|
|
| Oramed Pharmaceuticals Inc. announced that it has enrolled and randomized over 75% of the 675 patients planned for its Phase III ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes.
[Oramed Pharmaceuticals, Inc.] |
|
|
|
| Better Therapeutics, Inc. announced the completion of patient enrollment in its potentially pivotal study to evaluate the safety and efficacy of BT-001 for the treatment of type 2 diabetes.
[Better Therapeutics, Inc (BioSpace, Inc.)] |
|
|
|
|
| December 1 – 10, 2021
Virtual |
|
|
|
|
|
| Harvard Joslin Diabetes Center – Boston, Massachusetts, United States |
|
|
|
| NUI Galway – Galway, Ireland |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Harvard Medical School – Boston, Massachusettes, United States |
|
|
|
| University of California Los Angeles – Los Angeles, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
